These peptides regulate your appetite, blood sugar, and energy usage.
UCG / Contributor / Getty Images
What’s the Best Peptide for Weight Loss?
The U.S. Food and Drug Administration (FDA) has approved several peptide medications for weight management.
UCG / Contributor / Getty Images
These peptides include:
Do Peptides Really Work for Weight Loss?
Will it’s crucial that you Take Peptides for the Rest of Your Life?
The short answer is, possibly, yes.
Reaching aweight-loss plateautypically means your body’s metabolism has adapted, not that your medicine has stopped working.
Maintaining a healthy weight is a great accomplishment.
Do You Need a Prescription for Peptides for Weight Loss?
You’ll need a prescription from a healthcare provider for any FDA-approved injectable peptides.
How Much Weight Do You Lose on Peptides?
What Are Potential Side Effects and Risks of Peptides?
Who Should Consider Peptides for Weight Loss?
For this reason, it’s not always accurate.
For instance, BMI doesn’t distinguish between body fat and lean muscle.
It also doesn’t specify the location of the body fat.
Not everyone is a good candidate for peptide treatment.
These medicines help curb appetite, keep you full, and reduce food intake.
The amount of weight you’re able to expect to lose on peptides varies.
People without diabetes typically lose more weight than those who have diabetes.
Many people will need lifelong peptide treatment to maintain weight loss.
Gastrointestinal side effects include nausea, vomiting, and diarrhea.
2021;26(2):430.
2022;14(6):1271.
2023;44(1):60-67. doi:10.1093/asj/sjad211
U.S. Food and Drug Administration.OZEMPIC (semaglutide) injection prescribing information.
2024;52(1):3-7.
Published 2024 Mar 5. doi:10.2967/jnmt.123.266800
U.S. Food and Drug Administration.WEGOVY (semaglutide) injection prescribing information.
2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4
U.S. Food and Drug Administration.SAXENDA (liraglutide) injection prescribing information.
2020;9(Suppl 2):S149-S159.
2023;24(13):10449.
2015;50(3):117-128. doi:10.1097/NT.0000000000000092
